Visit our new Alternative Investment section.Click here

Less Ads, More Data, More Tools Register for FREE

IN BRIEF: Oxford Technology 2 VCT asset value hurt by AIM share falls

Fri, 22nd Sep 2023 13:05

Oxford Technology 2 VCT PLC - venture capital trust investing in quoted and unquoted technology companies - Net asset value of OT1 shares falls by 16% to 37.9 pence on August 31 from 45.3p on February 28. Similarly, NAV of OT2 shares falls to 20.5p from 25.1p, of OT3 shares to 23.6p from 33.7p, and of OT4 shares to 25.4p from 29.7p. No dividends are paid during the half year, nor are any shares bought back.

Oxford Technology says poor market conditions have caused its holdings in AIM listings Arecor Therapeutics PLC and Scancell Holdings PLC to lose value "despite them both continuing to report very encouraging technical, clinical and commercial progress".

Following the merger of all the OT VCTs, the company has "critical mass" but still is looking for a partner to expand its asset base.

"Regrettably we believe time is running out for us to be able to offer any such partner the use of our distributable reserves (the main attraction to enable them to pay early dividends to the new shareholders) without detriment to our existing shareholders," says Chair Richard Roth. "Whilst we will continue to engage with the two remaining leads, the board is also actively considering alternative plans to manage the rump portfolio, once our primary assets have been realised."

Says VCT will aim to keep costs low until holdings can be exited and proceeds distributed to shareholders.

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Oxford Technology 2 VCT Arecor Therape Scancell Holdings

Shares in this article

Related News

TRADING UPDATES: Conduit CFO Whelan to step down in September
28 Apr 2026

TRADING UPDATES: Conduit CFO Whelan to step down in September

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported...

Arecor Therapeutics swings to annual profit; hails insulin product
13 Apr 2026

Arecor Therapeutics swings to annual profit; hails insulin product

(Alliance News) - Arecor Therapeutics PLC on Monday highlighted the advancement of its lead product AT278, which is ultra-rapid-acting insulin, as it ...

IN BRIEF: Scancell names David Schilansky as interim finance chief
2 Apr 2026

IN BRIEF: Scancell names David Schilansky as interim finance chief

Scancell Holdings PLC - Oxford-based pharmaceutical company focused on cancer immunotherapies - Appoints "highly experienced senior healthcare executi...